About
MontA Biosciences develops a second-generation systemic TLR7 agonist formulated with proprietary lipid nanoparticles to target immune cells and enhance cancer immunotherapy by converting immune cold tumors into hot tumors responsive to treatment.
Explore Monta Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.